These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

838 related items for PubMed ID: 7522959

  • 21. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.
    Wang LG, Liu XM, Kreis W, Budman DR.
    Biochem Biophys Res Commun; 1999 May 27; 259(1):21-8. PubMed ID: 10334909
    [Abstract] [Full Text] [Related]

  • 22. Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression.
    Cheng H, Snoek R, Ghaidi F, Cox ME, Rennie PS.
    Cancer Res; 2006 Nov 01; 66(21):10613-20. PubMed ID: 17079486
    [Abstract] [Full Text] [Related]

  • 23. Induction of AP-1 activity by androgen activation of the androgen receptor in LNCaP human prostate carcinoma cells.
    Church DR, Lee E, Thompson TA, Basu HS, Ripple MO, Ariazi EA, Wilding G.
    Prostate; 2005 May 01; 63(2):155-68. PubMed ID: 15486991
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells.
    Gong J, Zhu J, Goodman OB, Pestell RG, Schlegel PN, Nanus DM, Shen R.
    Oncogene; 2006 Mar 30; 25(14):2011-21. PubMed ID: 16434977
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Androgen receptor (AR) expression in AR-negative prostate cancer cells results in differential effects of DHT and IGF-I on proliferation and AR activity between localized and metastatic tumors.
    Plymate SR, Tennant MK, Culp SH, Woodke L, Marcelli M, Colman I, Nelson PS, Carroll JM, Roberts CT, Ware JL.
    Prostate; 2004 Nov 01; 61(3):276-90. PubMed ID: 15368471
    [Abstract] [Full Text] [Related]

  • 30. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP.
    Swinnen JV, Esquenet M, Goossens K, Heyns W, Verhoeven G.
    Cancer Res; 1997 Mar 15; 57(6):1086-90. PubMed ID: 9067276
    [Abstract] [Full Text] [Related]

  • 31. Steroid receptor regulation of epidermal growth factor signaling through Src in breast and prostate cancer cells: steroid antagonist action.
    Migliaccio A, Di Domenico M, Castoria G, Nanayakkara M, Lombardi M, de Falco A, Bilancio A, Varricchio L, Ciociola A, Auricchio F.
    Cancer Res; 2005 Nov 15; 65(22):10585-93. PubMed ID: 16288052
    [Abstract] [Full Text] [Related]

  • 32. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
    Gravina GL, Festuccia C, Millimaggi D, Dolo V, Tombolini V, de Vito M, Vicentini C, Bologna M.
    Prostate; 2008 May 15; 68(7):793-801. PubMed ID: 18324645
    [Abstract] [Full Text] [Related]

  • 33. Exisulind and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells.
    Lim JT, Piazza GA, Pamukcu R, Thompson WJ, Weinstein IB.
    Clin Cancer Res; 2003 Oct 15; 9(13):4972-82. PubMed ID: 14581372
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Partial agonist/antagonist properties of androstenedione and 4-androsten-3beta,17beta-diol.
    Chen F, Knecht K, Leu C, Rutledge SJ, Scafonas A, Gambone C, Vogel R, Zhang H, Kasparcova V, Bai C, Harada S, Schmidt A, Reszka A, Freedman L.
    J Steroid Biochem Mol Biol; 2004 Aug 15; 91(4-5):247-57. PubMed ID: 15336702
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth.
    Yan J, Xie B, Capodice JL, Katz AE.
    Prostate; 2012 Feb 15; 72(3):244-52. PubMed ID: 21656835
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Camptothecin disrupts androgen receptor signaling and suppresses prostate cancer cell growth.
    Liu S, Yuan Y, Okumura Y, Shinkai N, Yamauchi H.
    Biochem Biophys Res Commun; 2010 Apr 02; 394(2):297-302. PubMed ID: 20206136
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 42.